ABSTRACT
Objective To explore the application of BCG polysaccharide nucleic acid injection in the treatment of skin diseases.Methods Selected in June 2015 to August 2016 period, in our hospital for skin disease treatment of 200 patients. According to the type of skin disease is divided into chronic eczema, chronic urticaria, alopecia areata and flat warts four groups, each group contains 50 patients. And then each group of patients were randomly divided into two groups, one group as a control group, a group as the observation group, each group of 25 cases. The control group was treated with traditional drug therapy, and the observation group needed to increase the use of BCG polysaccharide nucleic acid injection. The treatment period is for three months. To observe and compare the treatment effect of the control group and the experimental group after three months, that is, to observe and compare patients with chronic eczema, chronic urticaria, alopecia areata and flat warts of the four different types of skin diseases after three months of treatment effect. Results In the patients with chronic eczema, the effective rate of treatment was 96.0％ in the observation group and 68.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). The effective rate was 88.0％ in the observation group and 60.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the patients with alopecia areata, The effective rate of treatment was 84.0％ in the observation group and 72.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the patients with flat warts, The effective rate was 92.0％ and the effective rate was 68.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the different types of skin diseases, the effective rate of treatment was obvious Higher than the control group, the treatment effect was significantly better than the control group (P<0.05). Conclusion For patients with skin diseases using BCG polysaccharide nucleic acid injection for treatment, compared to the traditional drug treatment better. For the different types of skin diseases, the use of BCG polysaccharide nucleic acid injection for treatment can get the best therapeutic effect, so BCG polysaccharide nucleic acid injection in different types of skin disease clinical treatment is a worthy of use and Its promotion of the treatment.
ABSTRACT
Objective To evaluate the clinical efficacy of acupoint injection with BCG-polysaccharide nucleic acid (BCG-PSN) in treating bronchial asthma. Method Seventy-two patients with bronchial asthma were randomized into an acupoint injection group and a muscular injection group, 36 cases in each group. The acupoint injection group was intervened by acupoint injection with BCG-PSN to Zusanli (ST36) and Dingchuan (EX-B1) alternately, 1 mL for two points in total each time; the muscular injection group was intervened by muscular injection at the same dose and frequency, twice a week, for successive 3 months. The pulmonary function and asthma control test (ACT) were estimated before and after intervention and during March of the next year. Result After intervention, the FEV1 values were (80.97±2.31)% and (80.78±2.56)% respectively in the acupoint injection group and muscular injection group, and PEF values were (6.50±0.21)L/s and (6.48±0.25)L/s, and the between-group differences were statistically insignificant (P>0.05). The ACT score was (23.02±1.03) in the acupoint injection group, significantly better than (22.40±2.04) in the muscular injection group (P<0.05). The follow-up study showed that the ACT score in the acupoint injection group was superior to that in the muscular injection group (P<0.05). Conclusion Acupoint injection and muscular injection with BCG-PSN can equally improve the pulmonary function in bronchial asthma, while the acupoint injection can produce a more significant effect than muscular injection in improving ACT.
ABSTRACT
Objective: To study the effect of intracavitary infusion of Huachansu injection combined with polysaccharide nucleic acid fraction of Bacillus Calmette Guérin (BCG-PSN) or cisplatin in the treatment of the malignant pleural and peritoneal effusions. Methods: Seventy patients were randomly divided into two groups. Patients in the treatment group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 18 mL of BCG-PSN; patients in the control group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 60 mg of cisplatin once a week and the treatment lasted for 2-4 weeks. Results: For the treatment group, the response rate (complete response + partial response) was 83.3% in 24 cases with malignant pleural effusion and 63.6% in 11 cases with malignant peritoneal effusion. The total response rate was 77.1% (27/35) in the treatment group. The KPS score was elevated in 26 cases, stable in 7 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 69.2% in 13 cases with malignant peritoneal effusion. The total response rate was 80.0% (28/35). The KPS score was increased in 16 cases, stable in 11 cases, and decreased in 8 cases. There was no significant difference in clinical efficacy between the two groups (P > 0.05). Patients in the treatment group had less adverse reaction and a more improved living quality than those in the control group (P < 0.05). Conclusion: Intracavitary infusion of Huachansu injection combined with BCG-PSN or cisplatin was effective in the treatment of malignant pleural and peritoneal effusions, but Huachansu injection plus BCG-PSN had less toxicity especially for the advanced patients who can not tolerate the intracavitary chemotherapy.